Member Info for PJT12

"I tried ringing Jog for clarification this morning but there is no reply. Any thoughts?"

Just seen this, James, but having thought about it, they were probably out somewhere :-)

https://www.thisismoney.co.uk/money/experts/article-11446965/TONY-HETHERINGTON-airline-flying-law-Wizz-Air-UK.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html

dgdg1, thanks for that reassuring article.

Speculative, I know, but might any FO announcement now be looming ever larger now this is out of the way, something they'd have been waiting for?

Tissshhhhh, boom! Good answer. Here's here all day, folks. Don't forget to try the chicken.

Thank you, that is very helpful and makes a lot of sense. I am not one to blame others for my own investment decisions or lack of conviction and cannot blame the MMs where others do; They ain't running a charity and perhaps I just need to do a bit more reading on this front.

I guess my ultimate question is (naive as it may seem to some!), is the market controlled by supply / demand, MM manipulation or both? "Naive" perhaps on my part because I expect integrity within the markets. Please don't LOL if tempted!

Yes, but I've seen lesser news in other instances which would have seen this up 30% or more. I ask in all sincerity but as someone who usually does not trust AIM, based upon not being able to grasp this contradictory logic that I've seen previously.

Can someone sensible please explain to me 'why' or 'how' in the face of what have largely been so many 'buys' this morning the SP has not reacted accordingly in the face of favourable news? Is it purely down to manipulation or are my expectations just wrong with this share / situation?

From Endpoints

AstraZeneca and Merck executives are now raising concerns about how the IRA will impact cancer drug development moving forward as the clock for negotiations begins with the first approved indication.

On an investor call yesterday (this week), AstraZeneca CEO Pascal Soriot said that his company may no longer launch new cancer drugs in the US unless it’s for a large enough indication to keep that clock from starting too soon.

“There is a disincentive to start with small indications,” Soriot said on the call, adding:

That’s mostly true for oncology, where if you have to start with a third-line indication, patients would benefit from this, but we may not do it in the future or not launch in the U.S. We may launch elsewhere in the world, but not launch in the U.S. until we have approval for a larger indication, because the clock starts as soon as you get approval. So, that’s that. Those are really negative factors that are real problems with this.

Or?…....
https://www.biopharmadive.com/news/pharma-drug-pricing-ira-law-impact-negotiation/636110/

Do you think the fact that the company name sounds more like an NYC mafia outfit might be hindering the SP? Just asking :-)

.."BUT I get your point". A bit of the Allo Allo policeman crept in there. Too much ITV!

.....and you were doing so well before you mentioned Matt "The blimmin' Ego" Han****........bit I get your point.

Wish the CEO well. Sounded like very difficult time for him.

smorrisjones, believe me, that's "impressive" based upon some of the companies I've invest in :-)

Fuel costs screwed them, having quadrupled because they do not hedge, but they are addressing that.

In fairness, there've been dafter questions on here :-)

Yep, but having now looked at his previous posts, I think it must be me!

cj62, assuming you are not taking the pee, Avacta's LFT is used to test for Covid (or others can be used for various other ailments and pregnancy) whilst AV6000 is used to deliver chemotherapy drugs directly to a tumour. It is only once in the tumour that the chemo is released with minimal side effects or damage to the heart especially.